Welcure Drugs & Pharmaceuticals Ltd
Incorporated in 1992, Welcure Drugs and Pharmaceuticals Ltd is in the business of pharmaceutical and healthcare.[1]
- Market Cap ₹ 92.7 Cr.
- Current Price ₹ 0.75
- High / Low ₹ 1.45 / 0.48
- Stock P/E 3.38
- Book Value ₹ 0.83
- Dividend Yield 0.00 %
- ROCE 2.53 %
- ROE 4.18 %
- Face Value ₹ 1.00
Pros
- Stock is trading at 0.93 times its book value
- Company has delivered good profit growth of 194% CAGR over last 5 years
Cons
- Company has a low return on equity of 3.84% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 282 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 347 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24 | 313 | |
| Operating Profit | -0 | 0 | 0 | 0 | -0 | 0 | -0 | 0 | 0 | -0 | -0 | 1 | 34 |
| OPM % | -25% | 20% | 40% | 33% | -40% | 0% | -12% | 46% | 18% | 4% | 10% | ||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 | 3 | 36 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 22% | |||
| 0 | 0 | 0 | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 | 2 | 28 | |
| EPS in Rs | 0.00 | 0.00 | 0.01 | 0.00 | -0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.01 | -0.01 | 0.02 | 0.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 86% |
| 5 Years: | 214% |
| 3 Years: | 507% |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 71% |
| 5 Years: | 194% |
| 3 Years: | 377% |
| TTM: | 5757% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 32% |
| 3 Years: | 1% |
| 1 Year: | 10% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | 4% |
| Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 112 |
| Reserves | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -10 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 123 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41 | |
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 267 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 267 | |
| Total Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 267 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | -0 | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 | -222 | |
| -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 222 | |
| Net Cash Flow | -0 | 0 | -0 | 0 | -0 | 0 | -0 | 0 | 0 | -0 | 0 | 0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 282 | ||
| Inventory Days | 2,554 | |||||||||||
| Days Payable | 52 | |||||||||||
| Cash Conversion Cycle | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,784 | ||
| Working Capital Days | -1,186 | -876 | 36 | 81 | 73 | 46 | 0 | 0 | 0 | 2,092 | ||
| ROCE % | 120% | -67% | 0% | -40% | 133% | 25% | 10% | -13% | 3% |
Documents
Announcements
- Board Meeting Outcome for Outcome Of The Board Meeting-Allotment Of Bonus Shares 1m
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Oct - RTA confirms dematerialization and cancellation of physical share certificates for quarter ended 30 Sept 2025.
-
Intimation Of Record Date For Ascertaining The Eligibility Of The Shareholders Entitled To Stock Split/ Sub-Division Of Shares & Bonus Issue.
7 Oct - Record date Oct 16, 2025 for 1:10 stock split and 1:10 bonus (AGM Sep 27, 2025)
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 07 October,2025 Of Welcure Pharmaceuticals Limited
7 Oct - Board fixed Oct 16, 2025 record date for allotment of bonus shares and stock split.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 30 Sep
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
WDPL is engaged in the manufacture and
trade of a wide range of healthcare formulations.